CHEMILY, LLC
Atlanta, GA · Biotech · Private
Large-scale synthesis and commercialization of Fmoc-protected glycoamino acids (GAAs) as building blocks for glycopeptide and glycoprotein production
- Grants
- $1.9M
- 7 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2017201820192020202120222023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Chemo-enzymatic synthesis of nucleotide sugar libraries and therapy-relevant derivatives | $149,849 | |
| Federal grant | Department of Health and Human Services · Phase II · Chemo-enzymatic synthesis of nucleotide sugar libraries and therapy-relevant derivatives | $149,849 | |
| Federal grant | Department of Health and Human Services · Phase I · Large scale preparation of Glycoamino acids (GAAs) for expanded glycopeptides and glycoproteins synthesis | $296,769 | |
| Federal grant | Department of Health and Human Services · Phase II · Chemo-enzymatic synthesis of nucleotide sugar libraries and therapy-relevant derivatives | $342,067 | |
| Federal grant | Department of Health and Human Services · Phase II · Chemo-enzymatic synthesis of nucleotide sugar libraries and therapy-relevant derivatives | $341,906 | |
| Federal grant | Department of Health and Human Services · Phase II · Chemo-enzymatic synthesis of nucleotide sugar libraries and therapy-relevant derivatives | $341,906 | |
| Federal grant | Department of Health and Human Services · Phase I · Design and synthesis of a next generation glycobiology toolbox for cell surface labeling | $290,927 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1585 | BeneFix, Inc. | — | $8.6M |
| 1586 | H-CYTE, INC. | — | $11M |
| 1587 | REGENERIX LLC | — | — |
| 1588 | CHEMILY, LLC | — | — |
| 1589 | REGENTIS BIOMATERIALS LTD. | — | $6.5M |
| 1590 | LEXEO Therapeutics LLC | — | — |
| 1591 | THERANOSTEC INC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.